GlaxoSmithKline to fight US drug patent ruling

GlaxoSmithKline is to fight a US court ruling which invalidates patents for its Augmentin antibiotic drug.

GlaxoSmithKline is to fight a US court ruling which invalidates patents for its Augmentin antibiotic drug.

Teva Pharmaceuticals Industries, Geneva Pharmaceuticals and Ranbaxy Laboratories sued to invalidate three patents that protected Augmentin from generic competition until the end of this year.

You have reached your article limit. Already a subscriber? Sign in

Unlimited access starts here.

Try from only €0.25 a day.

Cancel anytime

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited